Sulodexide Decreases Albuminuria and Regulates Matrix Protein Accumulation in C57BL/6 Mice with Streptozotocin-Induced Type I Diabetic Nephropathy

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Yung, Susan ^a   Chau, Mel K M ^a   Zhang, Qing ^a   Zhang, Chen Zhu ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CREATININE; FIBRONECTIN; GLUCOSE; HEPARANASE; PERLECAN; PROTEIN KINASE C; SODIUM CHLORIDE; SULODEXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROGENESIS; KIDNEY FUNCTION; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; STREPTOZOCIN DIABETES;

ALBUMINURIA; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLUCOSE; GLYCOSAMINOGLYCANS; HUMANS; MALE; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MURINAE; MUS;

EID: 84872785696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054501     Document Type: Article

References (49)

1. Mauer SM, Lane P, Zhu D, Fioretto P, Steffes MW (1992) Renal structure and function in insulin-dependent diabetes mellitus in man. J Hypertens Suppl 10: S17-20.
2. Fioretto P, Caramori ML, Mauer M, (2008) The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 51: 1347-1355.
3. Thomas MC, Burns WC, Cooper ME, (2005) Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 12: 177-186.
4. Wolf G, Ziyadeh FN, (2007) Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106: p26-31.
5. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO, (1993) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119: 1079-1091.
6. Mason RM, Wahab NA, (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358-1373.
7. Border WA, (1994) Transforming growth factor-beta and the pathogenesis of glomerular diseases. Curr Opin Nephrol Hypertens 3: 54-58.
8. Russo LM, del Re E, Brown D, Lin HY, (2007) Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes 56: 380-388.
9. Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, et al. (2007) Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 293: F1657-1665.
10. Iozzo RV, Pillarisetti J, Sharma B, Murdoch AD, Danielson KG, et al. (1997) Structural and functional characterization of the human perlecan gene promoter. Transcriptional activation by transforming growth factor-beta via a nuclear factor 1-binding element. J Biol Chem 272: 5219-5228.
11. Conde-Knape K, (2001) Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev 17: 412-421.
12. Morita H, Yoshimura A, Inui K, Ideura T, Watanabe H, et al. (2005) Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol 16: 1703-1710.
13. Schlondorff D, Banas B, (2009) The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 20: 1179-1187.
14. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, et al. (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73: 1419-1425.
15. Decleves AE, Sharma K, (2010) New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol 6: 371-380.
16. Lauver DA, Lucchesi BR, (2006) Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 24: 214-226.
17. Harenberg J, (1998) Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev 18: 1-20.
18. Dedov I, Shestakova M, Vorontzov A, Palazzini E, (1997) A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 12: 2295-2300.
19. Skrha J, Perusicova J, Pont'uch P, Oksa A, (1997) Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract 38: 25-31.
20. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlova M, et al. (2002) Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13: 1615-1625.
21. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, et al. (2011) Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis 58: 729-736.
22. Janssen U, Riley SG, Vassiliadou A, Floege J, Phillips AO, (2003) Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int 63: 2162-2170.
23. Yung S, Tsang RC, Leung JK, Chan TM, (2006) Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta. Kidney Int 69: 272-280.
24. Yung S, Zhang Q, Zhang CZ, Chan KW, Lui SL, et al. (2009) Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum 60: 2071-2082.
25. Yung S, Cheung KF, Zhang Q, Chan TM, (2010) Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 21: 1912-1927.
26. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, et al. (2012) Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61: 208-216.
27. Menne J, Park JK, Boehne M, Elger M, Lindschau C, et al. (2004) Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 53: 2101-2109.
28. Lin CL, Wang FS, Kuo YR, Huang YT, Huang HC, et al. (2006) Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 69: 1593-1600.
29. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R, (2007) Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56: 1825-1833.
30. Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, et al (2009) Mouse models of diabetic nephropathy. J Am Soc Nephrol 20: 2503-2512.
31. van den Born J, van Kraats AA, Hill S, Bakker MA, Berden JH, (1997) Vessel wall heparan sulfate and transcapillary passage of albumin in experimental diabetes in the rat. Nephrol Dial Transplant 12 (Suppl 2): 27-31.
32. Tamsma JT, van den Born J, Bruijn JA, Assmann KJ, Weening JJ, et al. (1994) Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37: 313-320.
33. Templeton DM, Fan MY, (1996) Posttranscriptional effects of glucose on proteoglycan expression in mesangial cells. Metabolism 45: 1136-1146.
34. Kasinath BS, Grellier P, Choudhury GG, Abboud SL, (1996) Regulation of basement membrane heparan sulfate proteoglycan, perlecan, gene expression in glomerular epithelial cells by high glucose medium. J Cell Physiol 167: 131-136.
35. Yung S, Chen XR, Tsang RC, Zhang Q, Chan TM, (2004) Reduction of perlecan synthesis and induction of TGF-beta1 in human peritoneal mesothelial cells due to high dialysate glucose concentration: implication in peritoneal dialysis. J Am Soc Nephrol 15: 1178-1188.
36. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, et al. (2006) Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70: 2100-2108.
37. Maxhimer JB, Somenek M, Rao G, Pesce CE, Baldwin D Jr, et al. (2005) Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54: 2172-2178.
38. Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasmussen B, et al. (1995) Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 345: 421-422.
39. Tamsma JT, van der Woude FJ, Lemkes HH, (1996) Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol Dial Transplant 11: 182-185.
40. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, et al. (1992) Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 42: 285-291.
41. Ceol M, Nerlich A, Baggio B, Anglani F, Sauer U, et al. (1996) Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 74: 484-495.
42. Lewis EJ, Xu X, (2008) Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 31 (Suppl 2): S202-207.
43. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, et al. (2000) Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 11: 2324-2336.
44. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, et al. (2012) Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 23: 123-130.
45. Iozzo RV, (2005) Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 6: 646-656.
46. Rossini M, Naito T, Yang H, Freeman M, Donnert E, et al. (2010) Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant 25: 1803-1810.
47. Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, et al. (2007) Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 56: 346-354.
48. Wu D, Peng F, Zhang B, Ingram AJ, Kelly DJ, et al. (2009) PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells. J Am Soc Nephrol 20: 554-566.
49. Geraldes P, King GL, (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106: 1319-1331.